December 23, 2025

A new strategy for immune tolerance: Engineered extracellular vesicles show promise

December 23, 2025 / Research update / InnovateMed Author / immune tolerance

by Kanazawa University edited by Lisa Lock, reviewed by Robert Egan Editors’ notes Engineered antigen-presenting extracellular vesicles (AP-EVs) deliver peptide-MHCII, IL-2, and TGF-β to naïve antigen-specific CD4⁺ T cells, driving their differentiation into Foxp3⁺ regulatory T cells (Tregs). The induced Tregs suppress autoreactive T cells and modulate surrounding immune cells to promote antigen-specific immune tolerance. Credit: Drug Delivery (2025). DOI: […]

A new strategy for immune tolerance: Engineered extracellular vesicles show promise Read More »

Clearing the brain of aging cells could aid epilepsy and reduce seizures

December 23, 2025 / Research update / InnovateMed Author / epilepsy

by Georgetown University Medical Center edited by Sadie Harley, reviewed by Robert Egan Editors’ notes Credit: Pixabay/CC0 Public Domain Temporal lobe epilepsy, which results in recurring seizures and cognitive dysfunction, is associated with premature aging of brain cells. A new study by researchers at Georgetown University Medical Center found that this form of epilepsy can be treated in

Clearing the brain of aging cells could aid epilepsy and reduce seizures Read More »

AI-powered wearable boosts preventative care for elderly

December 23, 2025 / Research update / InnovateMed Author / preventive care

by Alexandra Pere, University of Arizona edited by Gaby Clark, reviewed by Robert Egan Editors’ notes Continuous gait monitoring for frailty detection. Credit: Nature Communications (2025). DOI: 10.1038/s41467-025-67728-y University of Arizona researchers in the Gutruf Lab have developed a comfortable, easy-to-use wearable device that incorporates artificial intelligence to detect subtle warning signs of frailty, signifying a leap forward in elderly

AI-powered wearable boosts preventative care for elderly Read More »

Brain injuries linked with potential risk of suicide

December 23, 2025 / Research update / InnovateMed Author / brain injury

by University of Birmingham edited by Stephanie Baum, reviewed by Robert Egan Editors’ notes Credit: Pixabay/CC0 Public Domain Adults who experience a head injury face a substantially higher risk of attempting suicide compared to those without such injuries, according to the findings from a new UK-based study. Published in Neurology, the study was led by University of Birmingham researchers.

Brain injuries linked with potential risk of suicide Read More »

How C-reactive protein outpaced ‘bad’ cholesterol as leading heart disease risk marker

December 23, 2025 / Research update / InnovateMed Author / heart disease

by Mary J. Scourboutakos, The Conversation edited by Gaby Clark, reviewed by Andrew Zinin Editors’ notes Credit: Unsplash/CC0 Public Domain Heart disease is the leading cause of death in the United States. Since researchers first established the link between diet, cholesterol and heart disease in the 1950s, risk for heart disease has been partly assessed based on a patient’s cholesterol

How C-reactive protein outpaced ‘bad’ cholesterol as leading heart disease risk marker Read More »

Cannabis products with more THC can slightly reduce pain but cause more side effects

December 23, 2025 / Clinical Practice / InnovateMed Author / THC

by Oregon Health & Science University edited by Sadie Harley, reviewed by Robert Egan Editors’ notes Credit: Unsplash/CC0 Public Domain A new systematic evidence review finds that cannabis products that carry relatively high levels of the psychoactive compound tetrahydrocannabinol, commonly known as THC, may provide short-term improvements in pain and function. However, the review found THC-based products led

Cannabis products with more THC can slightly reduce pain but cause more side effects Read More »

Menopause hormone therapy does not appear to impact dementia risk

December 23, 2025 / Clinical Practice / InnovateMed Author / menopause hormone

by University College London edited by Sadie Harley, reviewed by Robert Egan Editors’ notes Credit: Unsplash/CC0 Public Domain A major review of prior research has found no evidence that menopause hormone therapy either increases or decreases dementia risk in postmenopausal women, in a new study led by University College London (UCL) researchers. The findings, commissioned by the World

Menopause hormone therapy does not appear to impact dementia risk Read More »

AI translation is replacing interpreters in family medicine—here’s why that’s troubling

December 23, 2025 / Clinical Practice / InnovateMed Author / translation

by Anne Cronin, Anthony Kelly, The Conversation edited by Gaby Clark, reviewed by Andrew Zinin Editors’ notes Credit: Pixabay/CC0 Public Domain When a doctor can’t find an interpreter, many now reach for Google Translate. It seems like a practical fix to a pressing problem. But a new study warns this quick solution may be putting refugee and migrant

AI translation is replacing interpreters in family medicine—here’s why that’s troubling Read More »

Recommendations developed for managing adults with congenital heart disease

December 23, 2025 / Clinical Practice / InnovateMed Author / cogential heart disease

by Elana Gotkine edited by Gaby Clark, reviewed by Andrew Zinin Editors’ notes In clinical practice guidelines issued by the American College of Cardiology and American Heart Association and published online Dec. 18 in both the Journal of the American College of Cardiology and Circulation, recommendations are presented for the management of adults with congenital heart disease (ACHD). Michelle Gurvitz, M.D., from

Recommendations developed for managing adults with congenital heart disease Read More »

FDA approves Exdensur for severe asthma

December 23, 2025 / Clinical Practice / InnovateMed Author / asthma

by Lori Solomon edited by Gaby Clark, reviewed by Andrew Zinin Editors’ notes The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult and pediatric patients aged 12 years and older. Exdensur is the first and only long-acting biologic with an extended half-life

FDA approves Exdensur for severe asthma Read More »